Antiplatelet drugs are medications that are used to inhibit blood clot formation by interfering with platelet aggregation and adhesion. These drugs are commonly used for secondary prevention of cardiovascular events such as heart attacks and strokes. Some common antiplatelet medications include aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and others. The antiplatelet drugs market encompasses medication classes such as cyclooxygenase inhibitors, P2Y12 receptor inhibitors, and others.

The global antiplatelet drugs market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Rising prevalence of cardiovascular diseases is one of the major drivers spurring growth of the antiplatelet drugs market. According to the estimates provided by the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for over 17.9 million deaths each year. Growing geriatric population also makes them more prone to cardiovascular disorders. Various awareness campaigns by governments and healthcare organizations regarding benefits of antiplatelet drugs in preventing secondary cardiovascular events are also fueling market growth. Additionally, strong pipeline of novel antiplatelet drugs with better tolerability and efficacy will further aid expansion of the market over the forecast period. However, drug discontinuation and risks of excessive bleeding associated with antiplatelet drugs may hamper market growth to some extent.

SWOT Analysis
Strength: Antiplatelet drugs reduce cardiovascular disease risks and act as blood thinners by inhibiting platelet aggregation. Leading drugs like clopidogrel, ticagrelor, and prasugrel have strong efficacy and prevent clot formation effectively in three sentences or less. Patent expiries of major drugs between 2014-2020 lowered prices and improved access to therapy.
Weakness: Antiplatelet drugs increase risk of bleeding and bruising as a common side effect. Monitoring requirements and contraindications in certain patients undermine full compliance with medication in daily use.
Opportunity: Emerging economies are expected to drive volume growth due to increasing healthcare investment and awareness. New formulations focused on enhanced safety, tolerability and convenience represent opportunities.
Threats: biosimilars capturing market share threaten revenues of leading brands post-patent expiry. Stringent regulations and clinical trials required for new molecular entities limit the number of novel market entrants.

Key Takeaways
The global antiplatelet drugs market size is expected to witness high growth. The global Antiviral Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024-2031.

Regional analysis related content comprises Asia Pacific is projected to be the fastest growing region due to rising medical expenditures, healthcare reforms and growing efforts to expand insurance coverage in major markets like China and India.

Key players operating in the antiplatelet drugs market are Chang Chun Group, Covestro AG, Dow, and Hexio. Patent expiries of major drugs between 2014-2020 lowered prices and improved access to therapy globally.

Get more insights on this topic: https://www.newsstatix.com/antiplatelet-drugs-market-industry-insights-trends-antiplatelet-drugs-market/